Silver as biocides in burn and wound dressings and bacterial resistance to silver compounds
- 3.6k Downloads
Silver products have been used for thousands of years for their beneficial effects, often for hygiene and in more recent years as antimicrobials on wounds from burns, trauma, and diabetic ulcers. Silver sulfadiazine creams (Silvazine and Flamazine) are topical ointments that are marketed globally. In recent years, a range of wound dressings with slow-release Ag compounds have been introduced, including Acticoat, Actisorb Silver, Silverlon, and others. While these are generally accepted as useful for control of bacterial infections (and also against fungi and viruses), key issues remain, including importantly the relative efficacy of different silver products for wound and burn uses and the existence of microbes that are resistant to Ag+. These are beneficial products needing further study, although each has drawbacks. The genes (and proteins) involved in bacterial resistance to Ag have been defined and studied in recent years.
KeywordsSilver toxicity Medical uses of silver Industrial uses of silver Wound treatments Resistance mechanism
Commercially available Ag-containing dressings for wounds
Nature of product
Smith and Nephew, UK
Johnson and Johnson
Silver nylon cloth/activated charcoal
ConvaTec (Squibb Meyers)
Magnus Bio-Medical Technologies
Argentum Medical, Chicago
Silver nylon fabric
Silver absorbent wound dressing
Tegaderm Ag Mesh
Silver sulfate on mesh dressing
Westons Internet UK
Hydrocolloid polyester net
History of biocidal uses of silver products in clinical applications
For perhaps as long as 7000 years, the properties of silver in preventing diseases have been recognized, generally without knowing the basis (http://www.silvermedicine.org/history.html). For example, Alexander the Great (356–323 b.c.) was said to drink only from silver vessels, and this is attributed (more recently) to the antimicrobial activities of the released Ag+ cations . The Romans used silver nitrate therapeutically and silver was entered in the official Roman book of medicines (http://www.silentsoundcentre.com/id35.html). The alchemical writings of Paracelsus (1493–1541 a.d.) speak of the virtues of silver as a healing substance (http://www.auroville.com/vijnana/silver/history.htm, http://www.silverlon.com/history.html) .
The antibacterial qualities of silver were recognized as soon as bacteria were identified as disease-producing agents and silver was used in infectious disease medicine . Silver nitrate was introduced for treatment of skin ulcers, bone fractures, and suppurating wounds. K. S. F. Crede, a German obstetrician, introduced in 1884 the placing of AgNO3 solution in the eyes of newborn children to prevent gonorrheal infection [8, 34].
C. von Nägeli, also toward the end of the nineteenth century, recognized that silver functioned as an antibacterial agent at very low levels of Ag+ and coined the word “oligodynamic” (an unfortunate term) to mean that a small amount of silver is released  from the metallic surface when placed in contact with liquids. This term has been used widely in the published literature and medical brochures (http://www.discovervancouver.com/forum/topic.asp?TOPIC_ID=20888). The effect of low voltage direct current (DC) electricity in accelerating Ag+ release was recognized (e.g. [9, 11, 12, 35]), but definitive studies on the benefits of electrical stimulation are lacking. It is also difficult, sometimes, to generate DC potential at the bandage site.
At the beginning of the twentieth century, Albert C. Barnes in Philadelphia invented Argyrol (a silver protein solution; argyros is Greek for silver; http://www.neh.gov/news/humanities/2004-09/barnes.html) as a local antiseptic, especially to prevent eye infections. This product was the basis for Barnes’ personal fortune that he used to amass a notable French impressionist art collection and museum that is equally known for continuing litigation since his death, half-a-century ago. Barnes recognized that silver nitrate eye-drops often were caustic to human tissues and that a more benign and effective silver product could be produced by absorption of Ag+ on the surface of colloidal proteins such as gelatin. Some US states had laws requiring the specific product Argyrol (rather than AgNO3) for treatment of eyes of newborns.
Also early in the twentieth century, the surgeon William S. Halstead introduced the use of silver foil wound dressings (http://www.auroville.com/vijnana/silver/history.html), a use that continued until just after World War II, when antibiotics largely replaced silver. Nevertheless, use of silver foil dressings for wounds was listed in the Physician’s Desk Reference until 1955.
The most familiar human exposure to Ag is from dental amalgams that contain 35% Ag(0) and 50% Hg(0) . The slow release of Hg from amalgams is known to select for Hg-resistant bacteria in the gut . Ag is also released  and Ag-resistant oral bacteria were recently reported . Furthermore, it appears that Ag release from film processing, mining sites, and dental amalgams are large sources of Ag in human wastewaters where selection for Ag resistance might also occur (e.g. [5, 29]). As stated above, human exposure to Ag compounds generally has no serious adverse health effect [12, 50], although prolonged high-level use of silver preparations (often as “health-supplements”) can rarely result in problems.
A brief statement is appropriate about the misuses of silver compounds in personal hygiene and environmental applications. An Internet search for Argyria (from the Greek argyros for silver) will find many examples (http://www.silvermedicine.org/, http://www.colloidalsilver101.com/colloidalsilverliquid.html). Argyria occurs when subdermal Ag deposits results in an irreversible gray to blue-black coloring of the skin. It is the rare result of ingesting large amounts of silver preparations, usually as health stimulants . Argyria is permanent, but not physically harmful; it is an inherent serious cosmetic problem. Rosemary Jacobs (http://www.homepages.together.net/∼rjstan) is an opponent of silver-containing health products, who developed argyria as a teenager, as the result of long-term use of Ag-containing nasal drops. She has spoken against these products for nearly 50 years. Jacobs states that colloidal silver diet supplements and related products for human health and hygiene generally lack claimed values. That, however, does not affect the usefulness of Ag products on bandages and in wound treatment, and the possible (less clearly shown) benefits of Ag of treating domestic water and food sources.
Current bio-medical uses of silver products
Silver products are used in medicine in an expanding range of products. The most important current use is undoubtedly as a biocide to prevent infections of long-term problem sites including burns, traumatic wounds, and diabetic ulcers. Additional uses include coating of catheters and other devices implanted on or within the body. The hygienic uses including disinfecting water supplies expand the potential range.
Burns continue to be serious clinical problems. However, most deaths of burn patients today result from infections rather than the burns themselves. Modak et al. [45, 46] combined two useful antibacterial agents, silver nitrate and sulfadiazine, to form an extremely useful agent Silvazine. It is thought that Silvazine functions with the slow release of Ag+ as the primary biocide while sulfadiazine serves mostly to keep Ag+ in solution and to prevent the light-sensitive formation of black colloidal Ag0 on the skin surface, again a serious cosmetic problem with AgNO3-based products, since patients object to skin blackening . Silver sulfadiazine burn ointment  was licensed to Marion Laboratories (in 1969), with the US patent issued in 1973. The company producing Silvazine became Hoechst Marion Roussel (1995) after Hoechst acquired Marion Merrell Dow (formed by the merger of Marion Laboratories and Merrell Dow Pharmaceuticals) and silver sulfadiazine is now available from on-line catalogs, such as that from Sigma Chemical Co. (http://www.sigmaaldrich.com/catalog/search/ProductDetail/ALDRICH/481181). Of course, Hoechst was responsible for the first metalloid-based antimicrobial drug, the organoarsenic compound Salvarsan, almost 100 years earlier (in 1910). That marked the birth of chemotherapy with the first antimicrobial treatment for syphilis. Paul Ehrlich (1854–1915) found Salvarsan in his search for a “magic bullet” against disease-causing microbes. Silver sulfadiazine quickly became the drug of choice for burns, and is widely used to controlling bacterial infection. It is available commercially as a water-soluble ointment and was widely employed during the Vietnam War and since. However, patient discomfort from laborious application and cleaning (pain and lack of patient acceptance) remain with Silvazine, which as a cream-based product that must be spread on and removed from the burn surface repeatedly .
These products are useful for major medical problems including wide-body burns, sepsis in traumatic wounds, and chronic diabetic ulcers (e.g. http://www.fda.gov/cdrh/pdf4/k041316.pdf). Figure 2 shows a Silverlon bandage opened from its sterile foil wrapping and a roll of the same product being applied to a leg skin graft.
With the goal for products useful for human wounds in vivo in clinical settings, both in vivo testing on experimental animal wounds, e.g. [10, 36], and in vitro laboratory tests (such as disk zone inhibition assays; Fig. 3), and liquid bacterial killing curves [23, 60] are frequently used as substitutes and continue to be needed. At this time, most studies reported (e.g. [32, 48, 49, 58, 60]) have been preliminary and mostly not adequately controlled. Although it has long been recognized that chloride anions and serum proteins effectively remove free Ag+ from the wound environment  and therefore in vitro measurements cannot substitute for direct in vivo animal and human studies. Nevertheless, in vitro studies are useful as they are more rapid, cheaper and more carefully controlled. Further listing of the complexities and limitations of available published studies (and frequently unpublished studies available on corporate Internet sites) will not resolve these questions. What is needed today are new measurements comparing in vitro  and in vivo  tests based on better understanding of the complexities and realistic comparisons of available commercial products—all of which we anticipate will be beneficial in clinical settings.
The time of application (from minutes and hours for in vitro tests to days, weeks, and months for in vivo applications) and the complex relationship between slow Ag release from a bandage to its distant attack on infecting microbes remain problems differing between in vitro and in vivo tests and which need attention.
Starting in the early 1970s, Becker and coworkers [4, 57] in Syracuse, New York began the use of silver-coated fabrics for the treatment of complex bone infections. A. B. Flick and R. O. Becker developed broader clinical applications for silver nylon fabrics, which evolved into the current Silverlon product line (http://www.silverlon.com/). Chu et al. [9, 10, 11] studied the wound healing properties of silver-plated fabrics and in addition the benefit of direct DC current. O. M. Alvarez (http://www.juzousa.com/juzosilverstudies.html) also studied the effect of electrically activated silver-coated fabrics, on partial thickness skin wounds of the pig as an animal model, and Deitch et al. [15, 16, 35] studied the efficacy of these products on chronic human bone infections.
While the products listed in Table 1 are promising for control of bacterial, viral, and fungal infections, many key issues are unresolved. These include the differing efficacy of the various available silver products for different uses and the problems arising from Ag+-resistant microbes. In general, different products all share slow and biocidal release of silver from bandages. However, there is no perfect biocide; and each has its drawbacks (reviewed by [25, 52, 53, 54]).
Silver-treated catheters (e.g. ) are used to prevent bacterial colonization and associated infections. These include Algid Ag IV Patch, a silver alginate-containing disk with a slit in the middle to accommodate catheters (http://www.deroyal.com/Literature_Live%5Cderoyal%5Cnews%5Cmaintenance%5CPDF_files%5C354_algidex_patch_literature.pdf). Without biocides, catheters develop slime-containing biofilms that enhance further bacterial infection. There are no available clinical studies for the Algid product for the application reducing intravascular related sepsis. Silver-coated urinary tract catheters reduce frequencies of urinary track infection .
Microbial silver resistance
Many metal cations (Cd2+, Hg2+, Pb2+, and Tl+ are examples in addition to Ag+) are toxic and nonessential; and bacterial cells have genetically-determined resistance systems to each [55, 56]. Silver ions are highly toxic to all microorganisms, probably due to poisoning of membrane respiratory electron transport chains and components of DNA replication [6, 17, 19, 31, 37, 45, 50]. Bacterial Ag+ resistance has been reported repeatedly [7, 14, 30, 39, 43] but the genetic basis was not understood until recently [27, 28, 52, 53, 54]. Bacterial silver resistance, like that to other toxic metal ions, is frequently encoded by genes located on plasmids [14, 28], but also sometimes found encoded on the chromosome (reviewed by [55, 56]). For example, the determinant studied in most detail was originally found on Salmonella plasmid pMG101  and encodes resistances to Ag+, Hg2+, and tellurite, as well as to several antibiotics [27, 43]. Salmonella and Escherichia coli have in addition a related chromosomal Ag+ resistance determinant [20, 28, 52]. Metal ion resistances (such as that to Ag+) are frequently selected without awareness when antibiotics and metal salts are used as antiseptics. For example, in a random collection of enteric bacteria from a Chicago hospital, more than 10% had genes for Ag+ resistance .
Silver-resistant bacteria have been reported from other sources where silver exposure might be expected to select for resistance [1, 7, 14, 30]. Ag+-resistant E. coli mutants were step by step selected in the laboratory  and shown to have active Ag+ efflux, presumably due to a chromosomally encoded system, perhaps the CusCBFA system [20, 28], which had not been identified at that time. In addition, the E. coli mutant silver-resistant strains were deficient in outer membrane porin proteins .
The product of the last gene of the silver resistance determinant, SilP, is predicted to be a P-type ATPase, a member of another large family of homologous heavy-metal cation resistance efflux ATPases [55, 56]. Structural data are available on the related Ca2+ P-type efflux ATPase (reviewed recently by ). These ATPases contain a membrane component (Fig. 4) and three intracellular domains referred to as the activator (A), nucleotide binding (N) and phosphorylation (with aspartate, D) domains. There are several important canonical features in the SilP P-type ATPase sequence, starting from the N-terminus proximal poly-histidine (H5DH2) presumed Ag+-binding domain in the cytoplasm that is considered equivalent to but different from the Cu2+-binding motif which includes a cysteine-X2-cysteine sequence found in related ATPases from bacterial to human sources (e.g. ), including the closely related E. coli CopA copper P-type ATPase. The SilP and CopA sequences are unrelated for the N-terminal cation recognition domains of about 275 amino acids and then closely similar for the remaining regions, including eight predicted trans-membrane alpha-helical regions (Fig. 4; [2, 55]) with a CPC tripeptide that is considered part of the transport pathway in the fourth of these trans-membrane sequences. This proline is conserved in all P-type ATPases regardless of substrate and the CPC is characteristic of a class of presumed Cu+ and Ag+ trans-locating ATPases .
The silver resistance determinant is unique among resistance systems in encoding two energetically different efflux pumps. The SilF periplasmic chaperone protein that is thought to carry Ag+ from its periplasmic site of release by SilP to the periplasmic uptake site of SilA, as part of the SilCBA complex (Fig. 4). With two periplasmic Ag+-binding proteins ascribed different functions in Fig. 4, one can ask about their relationships. SilE and SilF are basically unrelated, with SilE thought to form a largely alpha-helical secondary structure (Fig. 5a) with five Ag+ cations bound by ten histidine imidazole N atoms coordinating the cation binding  while the SilF homolog CusF forms a basically beta sheet structure with the cation bound by a single histidine (His58) N atom and two methionine (Met69 and Met71) S atoms (Fig. 5b) [3, 41]. The structures in Fig. 5 are preliminary as the structure of SilE is derived from circular dichroism and imidazole proton NMR analysis  and the structure for SilF/CusF available only for the CusF variant without bound cation . Nevertheless, these are unrelated periplasmic polypeptides with dissimilar monovalent cation-amino acid coordination. Sequence relationship “trees” for SilE and SilF proteins show that both families of polypeptides have tight clusters for known sequences of SilE and SilF (greater than 90% amino acid identities) plus secondary clusters of homologous protein sequences presumably for binding of other cations (PcoE for SilE and CusF for SilF are involved in copper resistance and approximately 50% identical in amino acid primary sequences). It seems likely that all four proteins, SilE, PcoE, SilF, and CusF, bind both monovalent cations Ag+ and Cu+, but not divalent cations such as Cu2+. Careful experimental measurements of cation preference and the sequence basis for binding are needed.
The sil genes known to date occur only on IncH incompatibility group plasmids, which are large, multiple antibiotic resistance plasmids . The plasmids with sil genes were originally isolated based on antibiotic resistances and from enteric bacteria from varying geographic locations. These initial findings suggest that Ag+ resistance might exist widely but is not known in the absence of a ready means of testing. A wide distribution of sil-homologous determinants localized on plasmids and on the bacterial chromosome might pose a threat toward effective use of silver compounds as biocides, analogous to the development of antibiotic-resistant bacteria when antibiotic usage increases indiscriminately [40, 51].
- 5.Belly RT, Kydd GC (1982) Silver resistance in microorganisms. Dev Indust Microbiol 23:567–577Google Scholar
- 8.Burrell RE (2003) A scientific perspective on the use of topical silver preparations. Ostomy Wound Manage 49(5A Suppl.):19–24. www.owm.comGoogle Scholar
- 18.Dunne SM, Gainsford ID, Wilson NH (1997) Current materials and techniques for direct restorations in posterior teeth. Part 1: silver amalgam. Internat Dental J 47:123–136Google Scholar
- 25.Gibbs RJ (1999) Silver colloids: do they work? Paperback, published by R. Gibbs, 40 pp, ISBN: 0967699207Google Scholar
- 49.Richard JW III, Spencer BA, McCoy LF, Carino E, Washington J, Edgar P, Rosenblatt J, Goodheart R, Heggers JP ((2002) Acticoat™ versus Silverlon®: the truth. J Burns 1:11–19Google Scholar
- 54.Silver S, Lo J-F, Gupta A (1999) Silver cations as an antimicrobial agent: clinical uses and bacterial resistance. APUA Newslett 17:1–3Google Scholar